USC researchers have identified potential new drug compounds that may reduce the brain inflammation linked to Alzheimer’s disease, especially in people with the high-risk APOE4 gene. The compounds target cPLA2, an enzyme that seems to fuel harmful inflammation while also being important for normal brain activity.